We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Gilead (GILD) Veklury Data Positive in Hospitalized COVID Patients
Read MoreHide Full Article
Gilead Sciences, Inc. (GILD - Free Report) announced positive data on Veklury (remdesivir) from three retrospective studies of the real-world treatment of patients hospitalized with COVID-19 at the World Microbe Forum (WMF).
Data from these three real-world analyses showed that in the overall patient population, patients who received Veklury treatment had a significantly lower risk for mortality compared with matched controls. Further, a reduction in mortality was observed across a spectrum of baseline oxygen requirements.
These positive results were consistently observed at different timeframes over the course of the pandemic and across geographies. In addition, data from two of the studies showed that patients who received Veklury had a significantly increased likelihood of discharge from the hospital by day 28.
We note that Veklury is indicated for adults and pediatric patients (12 years of age and older and weighing at least 40 kg) for the treatment of COVID-19 requiring hospitalization in the United States.
Data from the double-blind, placebo-controlled ACTT-1 study of hospitalized patients with COVID-19 showed that there was a trend toward reduced mortality at day 29 in Veklury-treated patients (n=541) compared with placebo (n=521) in the overall study population. However, this result was not statistically significant.
These real word analyses can help clinicians with additional data on the efficacy of Veklury in patients hospitalized with COVID-19, including its effect on mortality and likelihood of discharge from the hospital.
Gilead’s stock has gained 15.6% this year against the industry's decline of 1%.
Image Source: Zacks Investment Research
Incremental sales of Veklury had boosted the company’s first-quarter results and the same trend has likely continued in the second quarter as the pandemic created havoc in many countries like India. With emerging variants, drugs and treatments to cure the infected are also gaining significance along with vaccines.
Regeneron’s (REGN - Free Report) antibody cocktail, REGEN-COV (casirivimab and imdevimab), is currently authorized in the United States under an Emergency Use Authorization (EUA) to treat mild-to-moderate COVID-19 in adults and pediatric patients (12 years of age and older, weighing ≥40 kg) with positive results of direct SARS-CoV-2 viral testing.
The FDA granted an EUA to Vir Biotechnology (VIR - Free Report) and GlaxoSmithKline’s (GSK - Free Report) monoclonal antibody, sotrovimab, for the treatment of mild-to-moderate COVID-19 in adults and pediatric patients.
Each was hand-picked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2020. Each comes from a different sector and has unique qualities and catalysts that could fuel exceptional growth.
Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.
Image: Bigstock
Gilead (GILD) Veklury Data Positive in Hospitalized COVID Patients
Gilead Sciences, Inc. (GILD - Free Report) announced positive data on Veklury (remdesivir) from three retrospective studies of the real-world treatment of patients hospitalized with COVID-19 at the World Microbe Forum (WMF).
Data from these three real-world analyses showed that in the overall patient population, patients who received Veklury treatment had a significantly lower risk for mortality compared with matched controls. Further, a reduction in mortality was observed across a spectrum of baseline oxygen requirements.
These positive results were consistently observed at different timeframes over the course of the pandemic and across geographies. In addition, data from two of the studies showed that patients who received Veklury had a significantly increased likelihood of discharge from the hospital by day 28.
We note that Veklury is indicated for adults and pediatric patients (12 years of age and older and weighing at least 40 kg) for the treatment of COVID-19 requiring hospitalization in the United States.
Data from the double-blind, placebo-controlled ACTT-1 study of hospitalized patients with COVID-19 showed that there was a trend toward reduced mortality at day 29 in Veklury-treated patients (n=541) compared with placebo (n=521) in the overall study population. However, this result was not statistically significant.
These real word analyses can help clinicians with additional data on the efficacy of Veklury in patients hospitalized with COVID-19, including its effect on mortality and likelihood of discharge from the hospital.
Gilead’s stock has gained 15.6% this year against the industry's decline of 1%.
Incremental sales of Veklury had boosted the company’s first-quarter results and the same trend has likely continued in the second quarter as the pandemic created havoc in many countries like India. With emerging variants, drugs and treatments to cure the infected are also gaining significance along with vaccines.
Regeneron’s (REGN - Free Report) antibody cocktail, REGEN-COV (casirivimab and imdevimab), is currently authorized in the United States under an Emergency Use Authorization (EUA) to treat mild-to-moderate COVID-19 in adults and pediatric patients (12 years of age and older, weighing ≥40 kg) with positive results of direct SARS-CoV-2 viral testing.
The FDA granted an EUA to Vir Biotechnology (VIR - Free Report) and GlaxoSmithKline’s (GSK - Free Report) monoclonal antibody, sotrovimab, for the treatment of mild-to-moderate COVID-19 in adults and pediatric patients.
Gilead currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
5 Stocks Set to Double
Each was hand-picked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2020. Each comes from a different sector and has unique qualities and catalysts that could fuel exceptional growth.
Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.
Today, See These 5 Potential Home Runs >>